publication date: Mar. 31, 2016

NCI CTEP-Approved Trials for the Month of March

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

10004: A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL). NCI Center for Cancer Research; Waldmann, Thomas Alexander. (301) 496-6656

 

9882: Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2’- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers. Rhode Island Hospital; Kinsella, Timothy James. (401) 444-6203

 

Phase II

AOST1521: A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Kopp, Lisa M. (520) 626-2021

 

Other Phases

AALL15B2-Q: Use of DNA Methylation Assessment by xMELP for Prognosis in Pediatric Patients with T-ALL. Children’s Oncology Group; Wertheim, Gerald. (267) 970-5918

 

AALL15B7-Q: Role of the MAPK/ERK Pathway in Relapsed Pediatric B-Lymphoblastic Leukemia: Prognostic Implications and Potential for Targeted Therapy. Children’s Oncology Group; Carroll, William L. (212) 263-9947

 

ANHL15B1-Q: B-Lineage Lymphoblastic Lymphoma … Continue reading CCL March – NCI CTEP-Approved Trials for the Month of March

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.